# Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

> **NCT05028829** · PHASE2 · RECRUITING · sponsor: **Raymond Chung** · enrollment: 60 (estimated)

## Conditions studied

- Liver Fibroses
- Cirrhosis

## Interventions

- **DRUG:** Atorvastatin 20mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05028829
- **Lead sponsor:** Raymond Chung
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2031-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028829, "Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05028829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*